20 minute delayed data provided by Yahoo. Pipex Pharmaceuticals makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

Pipex Pharmaceuticals, Inc. ("Pipex") AMEX:PP is a development-stage, specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of central nervous system and autoimmune diseases. Our strategy is to exclusively in-license proprietary, clinical-stage drug candidates that have demonstrated clinical efficacy and to complete the further clinical testing and manufacturing sufficient to seek marketing authorizations via the filing of new drug applications (NDAs) with the FDA and marketing application authorizations (MAAs) with the European Medicines Evaluation Agency (EMEA).

Current Product Pipeline:

Trimesta:

Trimesta Timeline

Relapsing Remitting Multiple Sclerosis

We are developing Trimesta™ as an oral, immunomodulatory and anti-inflammatory agent for the North American market. Estriol has been approved and marketed throughout Europe and Asia as a mild estrogenic agent for over 40 years for the treatment of post-menopausal hot flashes.
Read More»

Zinthionein:

Zinthionein Timeline

Dry AMD

We are developing Zinthionein™ (oral zincmonocysteine), an orally active compound for the treatment of dry age-related macular degeneration (AMD). Oral ZMC the activity of antioxidant enzymes catalase and glutathione peroxidase, and the antioxidant protein metallothionein in cultured retinal pigment epithelial cells more efficiently and potently than currently available zinc formulations. These complexes are the subject of a recently issued U.S. Patent covering its composition of matter and a patent application and various uses thereof. Zinthionein™ has completed an 80 patient phase II clinical trial for the treatment of Dry AMD.
Read More»

Effirma:

Oral ZMC Timeline

Fibromyalgia Syndrome

We are developing EFFIRMA (oral flupirtine), a novel, centrally-active, oral therapy for the treatment of fibromyalgia syndrome (FMS) and we plan to conduct a limited, controlled phase II proof-of-concept clinical trial in this indication. FMS is a common, centrally-mediated pain disorder characterized by chronic diffuse pain and other symptoms.
Read More»

Anti-CD4 802-2:

Anti-CD4 802-2 Timeline

Graft Vs. Host Disease

We are developing a series of rationally-designed, small molecule/peptidomimetic inhibitors of the T-cell CD4 co-receptor. The CD4 co-receptor is central to a number of autoimmune disorders such as MS. Our anti-CD4 molecules are designed to selectively block the dimerization and oligomerization of adjacent CD4 receptors via the D1 domains of such receptors.
Read More»

Correcta:

Correcta Timeline

Reflectory Pouchitis

We are developing CORRECTA™, a proprietary retention enema formulation of the widely used topical antifungal agent clotrimazole, for the treatment of acute refractory pouchitis, a subset of inflammatory bowel disease that is related to ulcerative colitis (UC).
Read More»